lifestyle.recentlegalnews.com

Author: Immunovant Inc.

Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026

May 11, 2026
Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

April 2, 2026
Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

February 12, 2026
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

January 26, 2026